Bin Wu

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 10

Top Topics

Radical Prostatectomy

Methicillin Resistant Staphylococcus Aureus

Drug Administration

Top Venues

International journal of clinical pharmacy

Journal of clinical medicine

Expert opinion on drug safety

British journal of clinical pharmacology

This page only lists publications with an associated author ORCID identifier.

Publications

Jinjian Gu, Yuting Guo, Bin Wu, Jinhan He
Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data. International journal of clinical pharmacy (2024)
Tianqi Liu, Ruonan Gao, Li Li, Bin Wu, Fengbo Wu
Analysis of the association between Janus kinase inhibitors and malignant skin tumors using the Food and Drug Administration Adverse Event Reporting System. International journal of clinical pharmacy (2023)
Chunyan Wei, Wanhong Yin, Zhiyao He, Bin Wu
Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System. Journal of clinical medicine 12 (10) (2023)
Yang Bai, Bin Wu, Liangwen Gou, Zhenwei Fang, Ting Xu, Tiejun Zhang, Yuwen Li
Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System. Journal of clinical medicine 12 (18) (2023)
Xiangjie Di, Xiao Liang, Chao Shen, Yuwen Pei, Bin Wu, Zhiyao He
Carbohydrates Used in Polymeric Systems for Drug Delivery: From Structures to Applications. Pharmaceutics 14 (4) (2022)
Min Luo, Bin Wu, Yuwen Li, Fengbo Wu
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19. International journal of clinical pharmacy 44 (5) (2022)
Chen Chen, Chenyu Zhang, Ziyan Jin, Bin Wu, Ting Xu
Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system. International journal of clinical pharmacy 44 (3) (2022)
Chen Chen, Bin Wu, Chenyu Zhang, Ting Xu
Angiotensin receptor-neprilysin inhibitor and sodium-dependent glucose cotransporter-2 inhibitor-associated renal injury: a pharmacovigilance study. Expert opinion on drug safety (2022)
Bin Wu, Pengfei Shen, Xi Yin, Lei Yu, Fengbo Wu, Chen Chen, Jian Li, Ting Xu
Analysis of adverse event of interstitial lung disease in men with prostate cancer receiving hormone therapy using the Food and Drug Administration Adverse Event Reporting System. British journal of clinical pharmacology (2022)
Chunyan Wei, Ying Liu, Aidou Jiang, Bin Wu
A pharmacovigilance study of the association between tetracyclines and hepatotoxicity based on Food and Drug Administration adverse event reporting system data. International journal of clinical pharmacy 44 (3) (2022)